AI-Based Aptamer Design & Aptamer Discovery Services
Accelerate aptamer discovery with AI-based aptamer design. Blackthorn AI helps biotech teams develop high-affinity aptamers faster-from in silico screening to optimized sequences
How We Improve Aptamer Discovery Efficiency
Lower Total Cost of Aptamer Development
By removing low-potential sequences early, teams typically reduce the cost of early discovery by 30–50%.
Shorter, More Predictable Discovery Cycles
Aptamer teams typically waste up to 60–80% of early discovery time cycling through unstable or low-value sequences.
De-Risking SELEX and Enrichment Workflows
Our optimization approach reduces these risks by prioritizing sequences with the highest probability of meaningful enrichment – so wet-lab teams start each round with a far stronger pool.
Delivering Higher-Quality Aptamer Candidates
Higher-quality profiles translate directly into higher hit rates during SELEX refinement and downstream development.
Reducing Wet-Lab Attrition Rates
We help teams avoid these failures by identifying weak or non-viable candidates before they reach the bench.
The team showed initiative and proactiveness in developing alternative solutions to reach our goals. As a result, we obtained very complex and high-quality support.
Under NDA
CEO, Chemistry Solutions CompanyBiotech
Industry
Drug Discovery, AI compound screening, Chemical space optimization
Services
USA
Location
$200,000 to $999,999
Budget
Who Benefits from AI-Based Aptamer Design
Aptamer Discovery & SELEX Providers
-
Companies that run systematic SELEX campaigns and need to reduce enrichment failures, improve hit quality, and accelerate project delivery for their clients.
Biotech Teams Developing Aptamer-Based Therapeutics
-
Teams advancing aptamers as drug candidates, where improved affinity, stability, and specificity directly translate into lower attrition rates and stronger downstream validation.
Diagnostics & Assay Development Companies
-
Organizations building aptamer-based diagnostics, biosensors, or analytical assays that rely on reproducible folding, high-selectivity binders, and fast iteration cycles.
Need a specialized aptamer solution?
Share your discovery goals. We’ll evaluate the feasibility of AI-driven generation and map out the optimal strategy for sequence optimization and validation.
These case studies illustrate how our AI-driven workflows help R&D organizations improve predictability, eliminate low-value candidates, and deliver better results with fewer experiments.
FAQ
Questions R&D teams ask
01How does AI help aptamer discovery?
It scores and ranks candidate sequences in silico before and between SELEX rounds, so low-potential and unstable sequences are removed early and each wet-lab round starts from a stronger pool.
02Does AI replace SELEX?
No. It makes SELEX more efficient by prioritizing sequences with the highest probability of meaningful enrichment and by flagging weak or non-viable candidates before they reach the bench. Lab validation stays the final test.
03Who is AI-based aptamer design for?
Aptamer discovery and SELEX providers, biotech teams developing aptamer therapeutics, and diagnostics and assay developers building aptamer-based biosensors or analytical assays.
04What do you need from us to start?
Your discovery goals and target, plus any SELEX or binding data you already have. We evaluate whether AI-driven generation is feasible and map out a strategy for sequence optimization and validation.
Let’s build your AI advantage
Whether you’re prototyping a molecule scoring system or looking to automate your clinical ops – we’ll help you turn your biotech data into competitive edge.